MBBS FRCP FRCPath PhD
Associate Professor of Haematology & Consultant Haematologist
- Cancer Research Divisional Lead, Thames Valley & South Midlands
- Myeloma Lead, Thames Valley Cancer Alliance
- Trustee, Myeloma UK Patient Charity
MRC CARP Fellow
Improving outcomes for patients with plasma cell dyscrasias
Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre https://oxford-myeloma.org.uk, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK and leads the National Haemonc Oversight Specialty group. He is an Executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy with collaborators is developing a national advisory service for Castleman disease. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his academic research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 100 papers and authored textbooks/ chapters on myeloma
Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort.
Maouche N. et al, (2021), J Oncol Pharm Pract
Multiple myeloma screening within a fracture liaison service (FLS).
Agarwal G. et al, (2021), Osteoporos Int
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
Ramasamy K. et al, (2021)
Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care.
Seesaghur A. et al, (2021), BMJ Open, 11
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Ramasamy K. et al, (2021), Blood Cancer J, 11